Compound Monograph

Casticin

Phenolics Flavonols Natural (plant-derived)

Casticin (vitexicarpin) is the HPLC standardization marker of chaste-tree (Vitex agnus-castus) fruit. Its own pharmacology is a broad but entirely preclinical anticancer literature — distinctive for a tubulin-binding, antimitotic mechanism alongside STAT3 and FOXO3a modulation — plus anti-inflammatory and immunomodulatory signals. Chaste-tree's clinical PMS/prolactin effects belong to the herb's dopaminergic diterpene extract, not to casticin.

Sources · 7

Where Does It Come From?

Casticin is a naturally occurring flavone (methoxyflavone), found in Chaste Tree fruit — QC standardization marker, Vitex trifolia and Vitex rotundifolia and 5 other sources. It is well tolerated orally (low toxicity).

Also found in
Artemisia Monograph coming soon
Chaste Tree fruit — QC standardization marker Monograph coming soon
Croton betulaster and other genera Monograph coming soon
Vitex trifolia and Vitex rotundifolia Monograph coming soon

Concentration

Content by Source

Concentrations not reported. No percent-dry-weight or mg/g figures have been published for this compound in its source plants.

Casticin at a Glance

Casticin (vitexicarpin) is one of the two HPLC standardisation markers of chaste-tree fruit, alongside agnuside — used to verify extract identity and strength.

Its own pharmacology is a broad but entirely preclinical anticancer literature, distinctive for a tubulin-binding, antimitotic mechanism — the same broad mode of action as vinca alkaloids and taxanes, which is unusual for a dietary flavone.

None of that relates to chaste tree’s clinical use, which is dopaminergic and prolactin-mediated.

What It's Used For

Casticin (vitexicarpin) is a hexasubstituted methoxyflavone — a relative of luteolin/apigenin and a sibling of the methoxyflavones eupatorin and jaceosidin — best known as the HPLC standardization marker of chaste-tree fruit. The load-bearing distinction for the whole page: casticin is a QC marker, and Vitex’s human PMS/mastalgia/prolactin-lowering evidence belongs to the herb’s dopaminergic labdane diterpenes / whole-fruit extract, not to casticin 3Reference 3Wuttke W et al. · 2003Chaste tree (Vitex agnus-castus) — pharmacology and clinical indicationsView study →.

Casticin’s own literature is a broad but entirely preclinical anticancer dataset — distinctive for a tubulin-binding, antimitotic mechanism — plus anti-inflammatory and immunomodulatory work. No human trial has ever dosed casticin as an isolate.

Broad preclinical anticancer activity with a distinctive mechanism:tubulin-binding/antimitotic arrest plus STAT3 suppression and FOXO3a activation across many tumor lines, with a few xenograft confirmations 4,8,11Reference 4Haïdara K et al. · 2006The flavonoid casticin has multiple mechanisms of tumour cytotoxicity (a tubulin-binding agent)View study →Reference 8Gong Q et al. · 2018Casticin suppresses the carcinogenesis of small-cell lung cancer H446 cells through AMPK/FoxO3a signallingView study →Reference 11Shang HS et al. · 2020AnimalCasticin inhibits the in-vivo growth of xenograft tumours of human oral cancer SCC-4 cellsView study →.
The honest headline:all preclinical, mostly in-vitro at µM concentrations; none of chaste-tree’s clinical trials belong to casticin (they are the extract’s diterpenes); human isolate exposure is a trivial ~0.14 mg/day marker quantity 3Reference 3Wuttke W et al. · 2003Chaste tree (Vitex agnus-castus) — pharmacology and clinical indicationsView study →.
Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. No human isolate data, so scores stay low by design despite the literature breadth.

Mechanisms

Target / pathwayEffectRelevant to
β-Tubulin / microtubulestubulin-binding → inhibits polymerization → mitotic (G2/M) arrest and catastrophe
anticancer (core mechanism); reproductive caution
p21↑ → Cdk1 inhibition; cyclin A↓cell-cycle arrest
anticancer
Bcl-2↓ / Bax; mitochondrial apoptosis; JNKapoptosis (retained in p53-null and Pgp-overexpressing cells)
anticancer (broad lines)
STAT3 (incl. JAK2/STAT3)suppressed → growth inhibition + radiosensitization
anticancer
FOXO3a (via AMPK; represses FoxM1)activated
anticancer
NF-κB; eosinophil migration; chemokines/adhesion moleculesinhibited
anti-inflammatory / anti-allergic
Macrophage / NK activity; lymphocyte proliferationenhanced; inhibited
immunomodulatory (bidirectional)

Pharmacokinetics

Casticin is a typical poorly-bioavailable methoxyflavone. Rat studies report low systemic exposure and rapid elimination, and metabolism work shows extensive phase-I/II biotransformation — demethylation plus glucuronidation/sulfation — consistent with high first-pass turnover 17Reference 17Ling Y et al. · 2012AnimalMetabolism studies of casticin in rats using HPLC-ESI-MSⁿView study →. The methoxy groups improve membrane permeability relative to hydroxylated flavones, but the compound is still subject to fast conjugative clearance, and there are no human pharmacokinetic data for the isolate. At herb-relevant exposure (~0.14 mg/day from a standardized chaste-tree dose), systemic casticin is negligible.

Clinical trials

There are no trials of the isolate. Casticin has never been administered to humans as a single compound for efficacy, PK or safety. All human Vitex agnus-castus trials (PMS, mastalgia, cyclical breast pain, hyperprolactinemia, PCOS) tested the whole standardized fruit extract, and their effects are attributed to the dopaminergic diterpene fraction — casticin serves only as an HPLC standardization marker there 3Reference 3Wuttke W et al. · 2003Chaste tree (Vitex agnus-castus) — pharmacology and clinical indicationsView study →.

CompletedPlannedTerminatedPreclinical
—(none, isolate)——Substantial(anticancer-dominated; some in-vivo)

Last checked: July 2026.

Toxicity & Safety

Real-world exposure to casticin is trivial — a fraction of a milligram a day as a chaste-tree marker — so the honest headline is that its antimitotic mechanism, not any observed toxicity, is what warrants caution, and it is the reason the pregnancy verdict is firm.

Safety at a Glance
Low / no toxicityDrug interactions
  • No observed toxicity signal. Nothing of concern surfaced for casticin itself, and the parent herb is well tolerated in trials.
  • Tubulin-binding antimitotic mechanism. An inherent, mechanism-based concern for rapidly dividing tissues — bone marrow, gut, gonads, embryo.
  • Avoid in pregnancy and lactation. Antimitotic mechanism plus a hormonally active source herb.
  • No isolate toxicology exists. The low flag rests on balance of evidence, not on a dedicated safety study.
  • Possible CYP modulation. Methoxyflavone herb–drug-interaction potential is plausible but not characterized for casticin.
Full Safety & Interactions Detail

Casticin’s low flag is chosen on the balance of evidence, with one honest caveat. No dedicated casticin toxicology of concern surfaced; the parent herb (Vitex agnus-castus) is well tolerated in trials; flavones generally show preferential toxicity toward transformed over normal cells; and human marker exposure is trivial (~0.14 mg/day). The one signal that could argue for a higher rating is casticin’s tubulin-binding/antimitotic mechanism 4Reference 4Haïdara K et al. · 2006The flavonoid casticin has multiple mechanisms of tumour cytotoxicity (a tubulin-binding agent)View study → — antimitotic agents carry an intrinsic, mechanism-based concern for rapidly dividing tissues (bone marrow, gut, gonads, embryo). Because that concern is theoretical at realistic exposures and there is no observed isolate toxicology, the flag is held at low while the antimitotic caution is surfaced explicitly and drives a firm pregnancy verdict. Methoxyflavone CYP-modulation herb–drug-interaction potential is plausible but not well characterized for casticin specifically.

Dosage

There is no established human dose — casticin has never been given to humans as an isolate, and all dosing in the literature is preclinical (µM in vitro; mg/kg in rodents) that does not translate. As a chaste-tree constituent, incidental intake is ~0.14 mg/day from a standardized daily dose — a QC-marker quantity, not a therapeutic one, so no human figure should be inferred.

References

  1. Chan EWC, et al. (2018). Casticin from Vitex species: a short review on its anticancer and anti-inflammatory properties. Journal of Integrative Medicine. https://pubmed.ncbi.nlm.nih.gov/29559215/
  2. Ramchandani S, et al. (2020). An overview of the potential antineoplastic effects of casticin. Molecules. https://pubmed.ncbi.nlm.nih.gov/32178324/
  3. Wuttke W, et al. (2003). Chaste tree (Vitex agnus-castus) — pharmacology and clinical indications. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/12809367/
  4. Haïdara K, et al. (2006). The flavonoid casticin has multiple mechanisms of tumour cytotoxicity (a tubulin-binding agent). Cancer Letters. https://pubmed.ncbi.nlm.nih.gov/16387422/
  5. Liu E, et al. (2013). Casticin induces human glioma cell death through apoptosis and mitotic arrest. Cellular Physiology and Biochemistry. https://pubmed.ncbi.nlm.nih.gov/23816816/
  6. Shen JK, et al. (2009). Casticin induces leukemic cell death through apoptosis and mitotic catastrophe. Annals of Hematology. https://pubmed.ncbi.nlm.nih.gov/19139893/
  7. Lee JH, et al. (2019). Casticin inhibits growth and enhances ionizing-radiation-induced apoptosis through suppression of the STAT3 signalling cascade. Journal of Cellular Biochemistry. https://pubmed.ncbi.nlm.nih.gov/30520154/
  8. Gong Q, et al. (2018). Casticin suppresses the carcinogenesis of small-cell lung cancer H446 cells through AMPK/FoxO3a signalling. Oncology Reports. https://pubmed.ncbi.nlm.nih.gov/30015975/
  9. He L, et al. (2013). Casticin induces growth suppression and cell-cycle arrest through activation of FOXO3a in hepatocellular carcinoma. Oncology Reports. https://pubmed.ncbi.nlm.nih.gov/23064420/
  10. Song XL, et al. (2017). Casticin induces apoptosis and G0/G1 cell-cycle arrest in gallbladder cancer cells. Cancer Cell International. https://pubmed.ncbi.nlm.nih.gov/28070171/
  11. Shang HS, et al. (2020). Casticin inhibits the in-vivo growth of xenograft tumours of human oral cancer SCC-4 cells. In Vivo. https://pubmed.ncbi.nlm.nih.gov/32871773/
  12. Lee H, et al. (2015). Casticin, an active compound from Vitex fructus, ameliorates cigarette-smoke-induced acute lung inflammation. International Immunopharmacology. https://pubmed.ncbi.nlm.nih.gov/26321116/
  13. Koh DJ, et al. (2011). Inhibitory effects of casticin on eosinophil migration and expression of chemokines and adhesion molecules in A549 lung epithelial cells. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/21251967/
  14. Lai KC, et al. (2019). Casticin promotes immune responses, enhances macrophage and NK-cell activities and increases survival in leukemia BALB/c mice. American Journal of Chinese Medicine. https://pubmed.ncbi.nlm.nih.gov/30630343/
  15. You KM, et al. (1998). Vitexicarpin, a flavonoid from the fruits of Vitex rotundifolia, inhibits mouse lymphocyte proliferation. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/9741302/
  16. Alam G, et al. (2002). Tracheospasmolytic activity of viteosin-A and vitexicarpin isolated from Vitex trifolia. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/12451502/
  17. Ling Y, et al. (2012). Metabolism studies of casticin in rats using HPLC-ESI-MSⁿ. Biomedical Chromatography. https://pubmed.ncbi.nlm.nih.gov/22407499/